...Hi, everyone. Thank you so much for being here today. For those of you that don't know me, my name is Courtney Breen, I cover large-cap biopharma here at Bernstein. I have spent a little while covering a lot of different companies, but my experience before being here was at Merck and spending a lot of time thinking about oncology. So I'm looking forward to this conversation today and getting to chat about kind of the work that's happening at Exelixis. I am privileged to share the stage today with Michael Morrissey, the CEO of Exelixis, and I will ask you to spend a couple of minutes perhaps giving a little bit of your background, kind of any high notes on the story that you would like to contextualize and then we'll dive into Q&A. A reminder for everyone in the room, please feel free to send through questions on the pigeon hole app, and I can integrate those into the conversation as well. Michael Morrissey ...
